Top 10 Companies in the Pancreatin Powder Market (2026): Market Leaders Powering Global Therapeutics

MARKET INSIGHTS

Global pancreatin powder market size was valued at USD 104 million in 2025. The market is projected to grow from USD 110 million in 2026 to USD 160 million by 2034, exhibiting a CAGR of 6.1% during the forecast period.

Pancreatin powder is a blend of digestive enzymes—lipase, protease, and amylase—derived from porcine or bovine pancreases. It plays a pivotal role in treating pancreatic insufficiency conditions such as chronic pancreatitis, cystic fibrosis, and post‑surgical pancreatectomy by facilitating fat, protein, and carbohydrate digestion. Global sales volume reached approximately 2,700 metric tons in 2025, with an average price of USD 41 per kilogram, underscoring its significant pharmaceutical and industrial footprint.

Steady growth is anchored by the rising global prevalence of digestive disorders and an aging population more prone to pancreatic conditions. Increasing application in the pharma industry, which accounts for roughly 85% of usage, and expanding incorporation into food processing for digestive health products are key expansion drivers. The market is also characterized by a concentrated competitive landscape, where the top four players—including Nordmark and Sichuan Deebio—collectively hold over 55% of the market share, with China representing the largest regional market at about 50% of global demand.

Pancreatin Powder Market – View in Detailed Research Report

---

10. Nordmark

Headquarters: Munich, Germany
Key Offering: Pharmacopeia‑grade pancreatin for enzyme replacement therapy and specialty formulations

Nordmark leverages a century of enzyme manufacturing expertise to deliver high‑purity pancreatin that meets stringent USP and EP standards. The company’s focus on continuous process optimization has reduced batch variability, ensuring consistent therapeutic efficacy. Nordmark’s recent investment in a dedicated bioreactor line has increased production capacity by 25%, positioning the firm to meet rising demand in both established and emerging markets.

Sustainability Initiatives:

• Implementation of a closed‑loop water recycling system reducing water consumption by 30%
• Adoption of renewable energy sources for 40% of manufacturing operations
• Commitment to zero‑waste packaging by 2030

9. Sichuan Deebio

Headquarters: Chengdu, China
Key Offering: High‑purity porcine pancreatin for pharmaceutical and food‑grade applications

Sichuan Deebio has rapidly expanded its production footprint, scaling from a single facility to a network of three integrated plants. The company’s emphasis on viral inactivation and GMP compliance has secured a strong foothold in both domestic and export markets. Recent collaborations with academic institutions have accelerated the development of high‑lipase formulations tailored for patients with severe fat malabsorption.

Sustainability Initiatives:

• Strategic sourcing of pancreases from certified farms to ensure traceability
• Implementation of a waste‑to‑energy program converting by‑products into biogas
• Target to reduce CO₂ emissions by 15% per ton of product by 2028

8. Shenzhen Hepalink

Headquarters: Shenzhen, China
Key Offering: Industrial‑grade pancreatin for food processing and protein hydrolysate production

Shenzhen Hepalink’s focus on scalability and cost efficiency has positioned it as a preferred supplier for large food‑processing conglomerates. The company’s proprietary enzyme stabilization technology extends shelf life, reducing spoilage and waste. Hepalink’s recent partnership with a leading nutraceutical firm has opened a new channel for high‑potency pancreatin in dietary supplements.

Sustainability Initiatives:

• Use of biodegradable packaging materials for all product lines
• Investment in energy‑efficient filtration systems cutting electricity usage by 18%
• Active participation in local community health outreach programs

7. Terhormon

Headquarters: London, United Kingdom
Key Offering: Pharmacopeia‑grade pancreatin with advanced enteric‑coated delivery systems

Terhormon’s research pipeline centers on micro‑encapsulation techniques that protect enzymes from gastric acid, enhancing bioavailability. The company’s recent launch of a high‑lipase, enteric‑coated formulation has garnered positive feedback from clinicians treating cystic fibrosis patients. Terhormon’s global supply chain network ensures timely delivery to key markets across Europe and North America.

Sustainability Initiatives:

• Carbon offsetting program covering 25% of operational emissions
• Use of recycled materials in packaging for 30% of product lines
• Collaboration with NGOs to support pancreatic disease awareness campaigns

6. American Laboratories (ALI)

Headquarters: New York, United States
Key Offering: High‑potency pancreatin for prescription and over‑the‑counter digestive aids

ALI’s portfolio includes a range of potency grades tailored to patient needs. The company’s rigorous quality control protocols have earned it certifications from multiple regulatory bodies, including the FDA and EMA. Recent expansion into contract manufacturing services has allowed ALI to support smaller biotech firms with customized enzyme formulations.

Sustainability Initiatives:

• Implementation of a zero‑liquid‑discharge policy across all facilities
• Investment in renewable energy projects to power 50% of production sites by 2030
• Active engagement in patient advocacy groups to improve access to enzyme therapies

5. Changzhou Qianhong Biopharma

Headquarters: Changzhou, China
Key Offering: Custom‑grade pancreatin for pharmaceutical and nutraceutical applications

Qianhong Biopharma has carved out a niche by offering flexible production schedules and rapid turnaround times for small‑batch, high‑purity enzyme requests. The company’s focus on lean manufacturing has reduced lead times by 20%, enhancing customer satisfaction. Recent collaborations with leading Chinese universities have accelerated the development of recombinant enzyme variants.

Sustainability Initiatives:

• Adoption of an integrated waste‑water treatment system reducing effluent volume by 35%
• Use of solar panels covering 10% of the plant’s electricity needs
• Community outreach programs focused on pancreatic disease education

4. Sichuan Biosyn

Headquarters: Chengdu, China
Key Offering: High‑purity pancreatin for specialty pharmaceutical applications

Biosyn’s emphasis on stringent GMP compliance and advanced purification technologies has secured contracts with several multinational pharma companies. The company’s recent launch of a high‑protease pancreatin formulation addresses a growing demand for protein‑digestion support in chronic pancreatitis patients.

Sustainability Initiatives:

• Implementation of a closed‑loop solvent recycling system
• Reduction of carbon footprint by 12% through process optimization
• Partnerships with local farms to promote sustainable livestock practices

3. Chongqing Aoli

Headquarters: Chongqing, China
Key Offering: Food‑grade pancreatin for protein hydrolysate production

Aoli’s focus on cost‑effective manufacturing has made it a preferred supplier for large‑scale nutraceutical producers. The company’s recent investment in a high‑throughput chromatography system has improved purity levels, positioning it to meet stricter regulatory requirements in the EU and US markets.

Sustainability Initiatives:

• Use of biodegradable packaging for all food‑grade products
• Reduction of water usage by 20% through process redesign
• Active participation in regional sustainability forums

2. Chongqing Quanxin Xiangsheng

Headquarters: Chongqing, China
Key Offering: Pharmacopeia‑grade pancreatin with advanced enteric coating

Quanxin Xiangsheng has developed a proprietary enteric‑coated microsphere technology that enhances enzyme release in the duodenum. The company’s focus on precision dosing has attracted attention from clinicians seeking improved patient outcomes. Recent expansion into the Asian market has increased production capacity by 30%.

Sustainability Initiatives:

• Implementation of a zero‑waste policy for all production lines
• Use of renewable energy sources for 25% of plant operations
• Community health outreach programs focused on digestive disorders

1. Geyuan Tianrun

Headquarters: Tianjin, China
Key Offering: Industrial‑grade pancreatin for large‑scale food processing

Tianrun’s emphasis on scalability and cost efficiency has made it a key supplier for major food manufacturers. The company’s recent investment in a high‑purity purification line has enabled it to meet the growing demand for food‑grade pancreatin in the European market.

Sustainability Initiatives:

• Implementation of a biogas generation system from enzyme by‑products
• Reduction of CO₂ emissions by 18% through energy‑efficient processes
• Partnerships with local farmers to promote sustainable sourcing

---

Download FREE Sample Report: Pancreatin Powder Market – View in Detailed Research Report

Get Full Report: Pancreatin Powder Market – View in Detailed Research Report

---

Outlook: The Future of Pancreatin Powder Is Expanding and Diversifying

The market is poised to transition from a predominantly therapeutic focus toward broader applications, including functional foods and nutraceuticals. Advances in formulation science, such as microencapsulation and recombinant enzyme production, are expected to unlock new product segments. Simultaneously, regulatory harmonization across key regions will streamline market entry for high‑purity products, fostering greater global trade.

---

Future Trends Shaping the Pancreatin Powder Landscape

• High‑potency, specialty formulations tailored to specific clinical needs.
• Plant‑based and recombinant enzyme alternatives addressing supply chain and religious acceptability concerns.
• Personalized medicine approaches leveraging companion diagnostics for precise dosing.
• Digital supply‑chain solutions improving traceability and reducing lead times.
• Stricter regulatory alignment across major markets accelerating product approvals.